PCVX logo

Vaxcyte (PCVX) Cash from operations

annual CFO:

-$452.63M-$155.84M(-52.51%)
December 31, 2024

Summary

  • As of today (June 28, 2025), PCVX annual cash flow from operations is -$452.63 million, with the most recent change of -$155.84 million (-52.51%) on December 31, 2024.
  • During the last 3 years, PCVX annual CFO has fallen by -$331.23 million (-272.86%).
  • PCVX annual CFO is now -1385.68% below its all-time high of -$30.47 million, reached on December 31, 2018.

Performance

PCVX Cash from operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXcash flow metrics

quarterly CFO:

-$166.27M-$54.87M(-49.26%)
March 31, 2025

Summary

  • As of today (June 28, 2025), PCVX quarterly cash flow from operations is -$166.27 million, with the most recent change of -$54.87 million (-49.26%) on March 31, 2025.
  • Over the past year, PCVX quarterly CFO has dropped by -$7.15 million (-4.49%).
  • PCVX quarterly CFO is now -1712.84% below its all-time high of -$9.17 million, reached on June 30, 2020.

Performance

PCVX quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXcash flow metrics

TTM CFO:

-$459.78M-$7.15M(-1.58%)
March 31, 2025

Summary

  • As of today (June 28, 2025), PCVX TTM cash flow from operations is -$459.78 million, with the most recent change of -$7.15 million (-1.58%) on March 31, 2025.
  • Over the past year, PCVX TTM CFO has dropped by -$51.55 million (-12.63%).
  • PCVX TTM CFO is now -4606.97% below its all-time high of -$9.77 million, reached on March 31, 2019.

Performance

PCVX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXcash flow metrics

Cash from operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

PCVX Cash from operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-52.5%-4.5%-12.6%
3 y3 years-272.9%-500.2%-238.3%
5 y5 years-860.1%-1119.6%-801.4%

PCVX Cash from operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-272.9%at low-500.2%at low-238.3%+2.2%
5 y5-year-870.7%at low-1712.8%at low-895.2%+2.2%
alltimeall time-1385.7%at low-1712.8%at low-4607.0%+2.2%

PCVX Cash from operations History

DateAnnualQuarterlyTTM
Mar 2025
-
-$166.27M(+49.3%)
-$459.78M(+1.6%)
Dec 2024
-$452.63M(+52.5%)
-$111.40M(+83.5%)
-$452.63M(-3.7%)
Sep 2024
-
-$60.71M(-50.0%)
-$470.04M(+0.7%)
Jun 2024
-
-$121.39M(-23.7%)
-$466.88M(+14.4%)
Mar 2024
-
-$159.12M(+23.5%)
-$408.22M(+37.5%)
Dec 2023
-$296.79M(+74.0%)
-$128.81M(+123.8%)
-$296.79M(+27.3%)
Sep 2023
-
-$57.55M(-8.3%)
-$233.20M(+8.9%)
Jun 2023
-
-$62.74M(+31.6%)
-$214.20M(+12.4%)
Mar 2023
-
-$47.69M(-26.9%)
-$190.59M(+11.7%)
Dec 2022
-$170.60M(+40.5%)
-$65.22M(+69.2%)
-$170.60M(+9.0%)
Sep 2022
-
-$38.55M(-1.5%)
-$156.47M(+6.9%)
Jun 2022
-
-$39.13M(+41.2%)
-$146.34M(+7.7%)
Mar 2022
-
-$27.70M(-45.8%)
-$135.89M(+11.9%)
DateAnnualQuarterlyTTM
Dec 2021
-$121.39M(+160.3%)
-$51.09M(+79.8%)
-$121.39M(+49.7%)
Sep 2021
-
-$28.41M(-0.9%)
-$81.07M(+23.4%)
Jun 2021
-
-$28.68M(+117.2%)
-$65.71M(+42.2%)
Mar 2021
-
-$13.21M(+22.6%)
-$46.20M(-0.9%)
Dec 2020
-$46.63M(-1.1%)
-$10.77M(-17.5%)
-$46.63M(-7.2%)
Sep 2020
-
-$13.05M(+42.3%)
-$50.27M(+7.7%)
Jun 2020
-
-$9.17M(-32.7%)
-$46.67M(-8.5%)
Mar 2020
-
-$13.63M(-5.4%)
-$51.01M(+8.2%)
Dec 2019
-$47.15M(+54.7%)
-$14.41M(+52.3%)
-$47.15M(+44.0%)
Sep 2019
-
-$9.46M(-30.0%)
-$32.74M(+40.6%)
Jun 2019
-
-$13.51M(+38.3%)
-$23.28M(+138.3%)
Mar 2019
-
-$9.77M
-$9.77M
Dec 2018
-$30.47M
-
-

FAQ

  • What is Vaxcyte annual cash flow from operations?
  • What is the all time high annual CFO for Vaxcyte?
  • What is Vaxcyte annual CFO year-on-year change?
  • What is Vaxcyte quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Vaxcyte?
  • What is Vaxcyte quarterly CFO year-on-year change?
  • What is Vaxcyte TTM cash flow from operations?
  • What is the all time high TTM CFO for Vaxcyte?
  • What is Vaxcyte TTM CFO year-on-year change?

What is Vaxcyte annual cash flow from operations?

The current annual CFO of PCVX is -$452.63M

What is the all time high annual CFO for Vaxcyte?

Vaxcyte all-time high annual cash flow from operations is -$30.47M

What is Vaxcyte annual CFO year-on-year change?

Over the past year, PCVX annual cash flow from operations has changed by -$155.84M (-52.51%)

What is Vaxcyte quarterly cash flow from operations?

The current quarterly CFO of PCVX is -$166.27M

What is the all time high quarterly CFO for Vaxcyte?

Vaxcyte all-time high quarterly cash flow from operations is -$9.17M

What is Vaxcyte quarterly CFO year-on-year change?

Over the past year, PCVX quarterly cash flow from operations has changed by -$7.15M (-4.49%)

What is Vaxcyte TTM cash flow from operations?

The current TTM CFO of PCVX is -$459.78M

What is the all time high TTM CFO for Vaxcyte?

Vaxcyte all-time high TTM cash flow from operations is -$9.77M

What is Vaxcyte TTM CFO year-on-year change?

Over the past year, PCVX TTM cash flow from operations has changed by -$51.55M (-12.63%)
On this page